Evidence map›Paper›PMID 33007496›Full record

ReviewTransplantation and cellular therapy2021

NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Carlos E Sanchez, Ehsan P Dowlati, Ashley E Geiger, Kajal Chaudhry, Matthew A Tovar, Catherine M Bollard, Conrad Russell Y Cruz

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Transplantation and cellular therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  8. Advanced T and Natural Killer Cell Therapy for Glioblastoma.Journal of Korean Neurosurgical Society · 2023
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Effects of Wild Yam Root (Cancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Carlos E SanchezProgram for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC.
Ehsan P DowlatiDepartment of Neurosurgery, Georgetown University Hospital, Washington, DC.
Ashley E GeigerProgram for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC.
Kajal ChaudhryProgram for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC.
Matthew A TovarSchool of Medicine and Health Sciences, George Washington University, Washington, DC.
Catherine M BollardProgram for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC; School of Medicine and Health Sciences, George Washington University, Washington, DC.
Conrad Russell Y CruzProgram for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC; School of Medicine and Health Sciences, George Washington University, Washington, DC. Electronic address: ccruz@childrensnational.org.
Children's National · USGeorge Washington University · USGeorgetown University · US

Funding

Enhancing cell therapy for brain tumorsU01CA239258 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI BOLLARD, CATHERINE M., CRUZ, CONRAD RUSSELL YOUNG · 2018 to 2022
$3.2M
NCI NIH HHS U01 CA239258
6 · The paper itself

Abstract

Natural killer (NK) cells, the primary effector cells of the innate immune system, utilize multiple strategies to recognize tumor cells by (1) detecting the presence of activating receptor ligands, which are often upregulated in cancer; (2) targeting cells that have a loss of major histocompatibility complex (MHC); and (3) binding to antibodies that bind to tumor-specific antigens on the tumor cell surface. All these strategies have been successfully harnessed in adoptive NK cell immunotherapies targeting cancer. In this review, we review the applications of NK cell therapies across different tumor types. Similar to other forms of immunotherapy, tumor-induced immune escape and immune suppression can limit NK cell therapies' efficacy. Therefore, we also discuss how these limitations can be overcome by conferring NK cells with the ability to redirect their tumor-targeting capabilities and survive the immune-suppressive tumor microenvironment. Finally, we also discuss how future iterations can benefit from combination therapies with other immunotherapeutic agents.

Indexed as

Immunotherapy, AdoptiveNeoplasmsHumansImmunotherapyKiller Cells, NaturalTumor MicroenvironmentADCCNK activating receptorsNK cellNK inhibitory receptorsTumor immunotherapy

Identifiers

PMID33007496
PMCPMC8043250
OpenAlexW3088789766

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.